Appeals Court Raises Bar for Pharma Whistleblowers, Citing Need for Solid Proof

Drug Industry Daily
A federal appeals court has raised the bar for whistleblowers filing False Claims Act (FCA) suits against drugmakers, saying they must provide specific information about the fraudulent claims made, not just broad allegations about a drugmaker’s conduct.

To View This Article:


Subscribe To Drug Industry Daily